A carregar...

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

Oncogenic mutations in RAS or BRAF can drive the inappropriate activation of the ERK1/2. In many cases, tumour cells adapt to become addicted to this deregulated ERK1/2 signalling for their proliferation, providing a therapeutic window for tumour-selective growth inhibition. As a result, inhibition...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sale, Matthew J, Cook, Simon J
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753831/
https://ncbi.nlm.nih.gov/pubmed/23647573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12220
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!